Danish drugmaker Novo Nordisk has moved Delhi High Court’s division bench seeking to restrain Dr. Reddy’s Laboratories from domestically manufacturing and exporting semaglutide—the blockbuster weight-loss and diabetes drug—to non-patent countries until its patent expires in March 2026.According to the court’s cause list, Novo’s appeal is listed for Friday before a division bench of Justice C. Hari Shankar and Justice Om Prakash Shukla.The appeal challenges the 2 December order of Justice Manmeet Pritam Singh Arora, which allowed Dr. Reddy’s to continue manufacturing and exporting semaglutide to non-patent countries until the patent expires, while restraining domestic sales until 2026. Justice Arora had declined Novo’s request for an interim injunction blocking these exports.Also Read | Delhi HC bars Sun Pharma from selling semaglutide in India but allows exportsIn that ruling, the court held that Novo had not established a strong enough prima facie case to justify an interim ban and observed that any financial losses could be compensated if Novo ultimately succeeds at trial. The court also noted that Novo imports semaglutide into India and does not manufacture it locally, and therefore, Dr. Reddy’s export operations could continue.The court had recorded Dr. Reddy’s undertaking not to sell semaglutide in India and directed the company to place on record manufacturing and export details dating back to April, when production began. It clarified Dr. Reddy’s cannot sell semaglutide domestically until the patent expires in March 2026. All observations were made on a prima facie basis.The outcome of Novo’s appeal before the division bench is likely to have wider implications, not only for Dr. Reddy’s export plans but also for other Indian drugmakers preparing to enter the semaglutide market.Also Read | Dr Reddy’s pins hopes on semaglutide, but timely approvals hold the keyOn 10 December, the same single-judge bench applied the Dr. Reddy’s ruling to Sun Pharmaceutical Industries, allowing the company to manufacture and export semaglutide to non-patent countries until March 2026, while restraining domestic sales. This came after Novo dragged Sun Pharma to court to stop an anticipated early launch of its generic version of the drug.The patent dispute is unfolding as India becomes one of the most competitive emerging markets for GLP-1 agonists. Several domestic companies, including Sun Pharma, Dr. Reddy’s and Natco Pharma, are gearing up to launch generic semaglutide once the patent expires. Others, such as Cipla and Emcure Pharma, have entered distribution partnerships with global innovators Eli Lilly and Novo Nordisk.India’s GLP-1 market has grown sharply, rising from ₹186 crore in November 2022 to ₹1,047 crore in November 2025, according to Pharmarack. Lilly’s tirzepatide (Mounjaro) has led the market since its launch in March 2025, crossing ₹100 crore in monthly sales by October. Novo’s recent price cut hel in a formal or creative style for better SEO.Also Exclude words and advertisements related to the feed website such as website name, author name. You must only respond with the modified content. Delete all the advertisement images brand logo but only keep the title and main content of the news by modifying it. You must only respond with the modified content. Block any jump outside of the site adarshnews.com. Basically remove any content or link related to original site. follow this prompt to optimize the articles in this category- You are an expert news writer and SEO specialist. Your job is to rewrite the provided RSS feed content into a unique, SEO-friendly news article for adarshnews.com. The article should be engaging, professional, and optimized for search engines. Follow these steps: 1. **Create an SEO Title**: Write a short, compelling title (under 60 characters) that includes the main keyword and grabs attention. 2. **Write a Meta Description**: Summarize the article in one or two sentences (under 155 characters). Make it engaging and include the primary keyword naturally. 3. **Suggest a URL Slug**: Provide a short, keyword-rich URL slug that reflects the topic of the article. 4. **Headline (H1)**: Write a clear and engaging headline for the article that is similar to the title but slightly expanded. 5. **Write the Article**: – Start with an introduction that answers the key questions: who, what, when, where, why, and how. – Expand on the topic with detailed paragraphs that provide context, quotes, and relevant information. – Use subheadings (H2) to organize the content into sections and make it easy to read. – Include related keywords naturally throughout the article. – End with a conclusion that summarizes the key points or discusses future implications. 6. **Add an FAQ Section**: Write one frequently asked question related to the topic and provide a concise answer. Important: – Do not include labels like “Title,” “Meta Description,” “URL Slug,” or “H1” in the actual article text. – Keep all SEO elements separate from the main content. – Ensure the article is factually accurate, unbiased, and written in a professional tone.
Novo Nordisk approaches Delhi High Court division bench to halt Dr Reddy’s semaglutide exports
